Drug Guide
Albuterol Sulfate; Budesonide
Classification
Therapeutic: Asthma and COPD agent
Pharmacological: Bronchodilator (Albuterol), Corticosteroid (Budesonide)
FDA Approved Indications
- Prevention and treatment of bronchospasm in asthma and COPD
Mechanism of Action
Albuterol is a beta-2 adrenergic agonist that relaxes bronchial smooth muscle, leading to bronchodilation. Budesonide is a corticosteroid that reduces airway inflammation by inhibiting multiple types of inflammatory cells and cytokines.
Dosage and Administration
Adult: Inhalation, 2 inhalations every 4 to 6 hours as needed. For maintenance, once or twice daily based on severity.
Pediatric: Dosing varies by age and severity; typically, 2 inhalations 2 times daily, with adjustments as directed by a healthcare provider.
Geriatric: Adjust dose based on response and tolerability; monitor for cardiovascular effects.
Renal Impairment: Use with caution; no specific dose adjustment required.
Hepatic Impairment: Use with caution; no specific dose adjustment required.
Pharmacokinetics
Absorption: Rapid for albuterol, variable for budesonide.
Distribution: Wide distribution; high first-pass metabolism for budesonide.
Metabolism: Albuterol is minimally metabolized; budesonide undergoes extensive first-pass metabolism in the liver.
Excretion: Renally excreted; approximately 70% of inhaled dose of budesonide is metabolized.
Half Life: Albuterol: approximately 3-5 hours; Budesonide: 2-4 hours (plasma half-life), but effects last longer.
Contraindications
- Hypersensitivity to albuterol or budesonide
Precautions
- Use with caution in patients with hypersensitivity reactions to corticosteroids; monitor for systemic corticosteroid effects; cardiovascular disease; diabetes; osteoporosis; fungal or bacterial infections of the respiratory tract.
Adverse Reactions - Common
- Throat irritation (Common)
- Cough (Common)
- Hoarseness (Common)
Adverse Reactions - Serious
- Paradoxical bronchospasm (Uncommon)
- Oral candidiasis (Uncommon)
- Adrenal suppression (with high doses) (Rare)
Drug-Drug Interactions
- Monoamine oxidase inhibitors, other sympathomimetics, beta-blockers, CYP3A4 inhibitors (e.g., ketoconazole)
Drug-Food Interactions
- Caffeine may increase side effects such as tremors or palpitations.
Drug-Herb Interactions
N/ANursing Implications
Assessment: Assess lung function (e.g., auscultation, PEF, FEV1), monitor for adverse reactions.
Diagnoses:
- Impaired gas exchange,
Implementation: Administer via inhalation device as prescribed; instruct patient on proper inhaler technique; monitor for adverse effects.
Evaluation: Evaluate improvement in respiratory symptoms; monitor for adverse effects such as tachycardia or oral thrush.
Patient/Family Teaching
- Instruct patient on proper inhaler technique.
- Advise to rinse mouth after inhalation to reduce oral candidiasis.
- Inform about possible side effects and when to seek medical attention.
Special Considerations
Black Box Warnings:
- Potential for systemic corticosteroid effects with inhaled corticosteroids, especially at high doses.
Genetic Factors: None specified.
Lab Test Interference: None significant.
Overdose Management
Signs/Symptoms: Severe tachycardia, hypokalemia, hyperglycemia, tremors.
Treatment: Supportive care; monitor cardiac and respiratory status; administer potassium if hypokalemia is severe.
Storage and Handling
Storage: Store at room temperature, 15-30°C (59-86°F).
Stability: Stable until expiration date on packaging.